Egypt : Complete Profile - What is GIS - World Health Organization

Health Systems Profile- Egypt Regional Health Systems Observatory- EMRO
Control Technical Committee (MCTC) establishes guidelines for provincial inspection
services for drugs and medical devices. The national quality control organization, in
cooperation with MCTC is setting up guidelines for quality assurance for drugs and
medical devices. Clinical trials of drugs are carried out in compliance with good clinical
practice
pricing
To promote the availability of safe and effective drugs at the lowest possible price, cost
is achieved by rationalizing the drug pricing system in the public and private sectors, and
by promoting the use of generic drugs
selection.
The selection of drugs on the national multi-level EDL is based on the following
criteria:
− must meet the health needs of the majority of the population
− sufficiently proven scientific data must be available regarding the effectiveness of
any such product
− products should have a substantial safety and risk to benefit ratio.
The National Organization for Drug Control and Research (NODCAR) represents the
empowered national regulatory authority for quality control.
NODCAR is entrusted with the quality control of pharmaceutical and biological
products, raw materials, cosmetics, veterinary products, medical devices, household
insecticides, medical plants and natural product as well as raw materials, and
packaging and filling materials.
In the last few years, the counterfeit medicine and smuggled drugs are considered
an international problem. To combat this phenomenon the Egyptian government
implements the following measures.
− appropriate legislation that identifies the import, national transit, and export of
counterfeit or smuggled goods into across and out of their customs
− new legislation that strengthens the penalty for persons who are involved in this
activity
− inspection and enforcement of control
− laboratory facilities for analytical tests of the products.
Reforms over the last 10 years
The Pharmaceutical Sector is an important component of the Health Sector Reform
Program (HSRP). Over the last two years, several activities have been completed as part
of reform of the Pharmaceutical Sector. The following is a summary of them:
Develop new organogram for Pharmaceutical Sector.
Develop new organogram for the National Organization for Drug Control and
Research (NODCAR).
Establish a new building for the MOHP Pharmaceutical Sector.
Develop PHC Essential Drug list.
Introduction of the new pharmaceutical system in MOHP facilities
Introduction of clinical pharmacy service in MOHP hospitals
Develop Essential Drug List manual for family health facilities.
Complete national survey for drug consumption at MOHP facilities.
95